暂无数据
关于我们
意见反馈
$ 2.11
-0.01(-0.4717%)
05-19 11:59
ORGENESIS INC
| 最高：2.30 | 今开：2.19 | 成交量：12.07万股 | 换手：0.49% |
| 最低：2.10 | 昨收：2.12 | 成交额：26.08万 | 振幅：9.43% |
| 52周最高：5.85 | 量比：1.00 | 市盈率(TTM)：亏损 | 市净率：1.36 |
| 52周最低：2.10 | 委比：-33.33% | 市盈率(静)：亏损 | 市销率：1.40 |
| 每股收益：-0.73 | 股息(TTM)：-- | 每手股数：1 | 总市值：5237.18万 |
| 每股净资产：1.59 | 股息率(TTM)：-- | 最小价差：0.01 | 总股本：2482.08万 |
| 机构持股：-- | Beta：-- | 空头回补天数：-- | 货币单位：USD |
财务指标
|
单位:美元
|
2018-05-31
|
2018-02-28
|
2017-11-30
|
2017-08-31
|
2017-05-31
|
|
流动资产
|
1,373.80万
|
856.90万
|
729.50万
|
567.40万
|
611.00万
|
|
现金及短期投资
|
567.70万
|
422.50万
|
351.90万
|
76.20万
|
65.80万
|
|
短期应收账款
|
342.40万
|
255.40万
|
221.00万
|
227.90万
|
309.50万
|
|
存货
|
122.90万
|
88.10万
|
72.50万
|
96.50万
|
90.40万
|
|
其他流动资产
|
340.80万
|
90.90万
|
84.10万
|
166.80万
|
145.30万
|
|
非流动资产
|
3,329.50万
|
3,384.20万
|
3,257.70万
|
3,174.80万
|
3,015.70万
|
|
厂房及设备净资产
|
751.70万
|
561.70万
|
510.40万
|
502.50万
|
480.70万
|
|
项目总投资及垫款
|
113.60万
|
205.10万
|
166.00万
|
48.10万
|
25.80万
|
|
长期应收票据
|
--
|
--
|
--
|
--
|
--
|
|
无形资产
|
2,456.00万
|
2,608.90万
|
2,573.50万
|
2,616.30万
|
2,501.70万
|
|
递延所得税资产
|
--
|
--
|
--
|
--
|
--
|
|
其他资产
|
8.20万
|
8.50万
|
7.80万
|
7.90万
|
7.50万
|
|
合计总资产
|
4,703.30万
|
4,241.10万
|
3,987.20万
|
3,742.20万
|
3,626.70万
|
|
流动负债
|
1,297.20万
|
1,616.40万
|
1,691.40万
|
1,757.10万
|
1,614.70万
|
|
短期债务（含部分LTD）
|
93.30万
|
195.80万
|
315.80万
|
316.50万
|
260.50万
|
|
应付账款
|
238.80万
|
383.80万
|
391.40万
|
368.90万
|
354.10万
|
|
应付所得税
|
--
|
--
|
--
|
--
|
--
|
|
其他流动负债
|
965.10万
|
1,036.80万
|
984.20万
|
1,071.70万
|
1,000.10万
|
|
非流动负债
|
213.80万
|
288.50万
|
522.90万
|
860.00万
|
1,022.20万
|
|
长期负债
|
190.20万
|
256.70万
|
453.30万
|
484.10万
|
505.60万
|
|
拨备风险及费用
|
5,000.00
|
6,000.00
|
6,000.00
|
5,000.00
|
5,000.00
|
|
递延所得税负债
|
3.20万
|
31.20万
|
69.00万
|
260.80万
|
202.70万
|
|
其他负债
|
19.90万
|
--
|
--
|
114.60万
|
313.40万
|
|
合计总负债
|
1,511.00万
|
1,904.90万
|
2,214.30万
|
2,617.10万
|
2,636.90万
|
|
股东权益合计
|
2,580.10万
|
1,947.80万
|
1,412.30万
|
1,125.10万
|
989.80万
|
|
非股权储备
|
--
|
--
|
--
|
--
|
--
|
|
优先股-账面价值
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
普通股权益（合计）
|
2,580.10万
|
1,947.80万
|
1,412.30万
|
1,125.10万
|
989.80万
|
|
累计少数股东权益
|
612.20万
|
388.40万
|
360.60万
|
--
|
--
|
|
权益总额
|
3,192.30万
|
2,336.20万
|
1,772.90万
|
1,125.10万
|
989.80万
|
|
负债与股东权益合计
|
4,703.30万
|
4,241.10万
|
3,987.20万
|
3,742.20万
|
3,626.70万
|
|
每股账面价值
|
1.94
|
1.90
|
1.43
|
1.14
|
1.00
|
|
每股账面价值-有形
|
0.09
|
-0.64
|
-1.18
|
-1.52
|
-1.52
|
|
单位:美元
|
2018-05-31
|
2018-02-28
|
2017-11-30
|
2017-08-31
|
2017-05-31
|
|
营业总收入
|
398.70万
|
263.60万
|
337.70万
|
256.20万
|
229.80万
|
|
-营业成本
|
264.00万
|
208.00万
|
233.70万
|
229.00万
|
152.50万
|
|
毛利
|
134.70万
|
55.60万
|
104.00万
|
27.20万
|
77.30万
|
|
-销售管理及行政费用
|
387.10万
|
411.00万
|
187.40万
|
368.40万
|
309.70万
|
|
-其他运营费用
|
--
|
--
|
--
|
--
|
--
|
|
计息税前利润
|
-252.40万
|
-355.40万
|
-83.40万
|
-341.20万
|
-232.40万
|
|
+非经营收入(支出)
|
-65.80万
|
29.00万
|
-113.80万
|
-16.90万
|
-132.70万
|
|
-非经常性支出
|
-60.60万
|
-11.70万
|
44.10万
|
-234.90万
|
-294.60万
|
|
-利息支出
|
17.70万
|
272.60万
|
24.60万
|
30.00万
|
29.80万
|
|
税前净利润
|
-275.30万
|
-587.30万
|
-265.90万
|
-153.20万
|
-100.30万
|
|
-所得税
|
-27.70万
|
-39.60万
|
-180.30万
|
42.10万
|
-44.40万
|
|
+其他税后调整
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
+联署公司盈利权益
|
--
|
--
|
--
|
--
|
--
|
|
合并净利润
|
-247.60万
|
-547.70万
|
-85.60万
|
-195.30万
|
-55.90万
|
|
-少数股东权益开支
|
13.80万
|
13.40万
|
--
|
--
|
--
|
|
净利润
|
-261.40万
|
-561.10万
|
-85.60万
|
-195.30万
|
-55.90万
|
|
-优先股股息
|
--
|
--
|
--
|
--
|
--
|
|
一般可用收入净利润
|
-261.40万
|
-561.10万
|
-85.60万
|
-195.30万
|
-55.90万
|
|
每股基本收益
|
-0.20
|
-0.52
|
-0.09
|
-0.24
|
-0.06
|
|
摊薄每股收益
|
-0.20
|
-0.52
|
-0.11
|
-0.24
|
-0.06
|
|
息税折旧摊销前利润
|
-187.90万
|
-291.70万
|
-11.00万
|
-274.50万
|
-170.90万
|
|
单位:美元
|
2017-11-30
|
2016-11-30
|
2015-11-30
|
2014-11-30
|
|
净收益
|
-1,236.70万
|
-919.40万
|
-446.10万
|
-550.41万
|
|
+折旧损耗及摊稍
|
259.80万
|
292.30万
|
199.10万
|
4,551.00
|
|
+递延税及投资税减免
|
-131.00万
|
-154.60万
|
-90.00万
|
--
|
|
+其他经营基金
|
467.00万
|
168.80万
|
-129.10万
|
339.36万
|
|
营运资金
|
-640.90万
|
-612.90万
|
-466.10万
|
-210.60万
|
|
+特别项目
|
--
|
--
|
--
|
--
|
|
+营运资金变动
|
257.60万
|
234.60万
|
195.50万
|
67.67万
|
|
经营现金流
|
-383.30万
|
-378.30万
|
-270.60万
|
-142.92万
|
|
资本支出
|
-97.50万
|
-142.50万
|
-98.20万
|
-4,746.00
|
|
收购所得净资产
|
--
|
--
|
30.50万
|
--
|
|
固定资产和业务出售收入
|
234.90万
|
--
|
--
|
--
|
|
投资买卖净额
|
-242.90万
|
-11.10万
|
-25.50万
|
--
|
|
非现金项目
|
0.00
|
0.00
|
0.00
|
7,255.00
|
|
投资现金流
|
-105.50万
|
-153.60万
|
-93.20万
|
2,509.00
|
|
发放现金股利
|
--
|
--
|
--
|
--
|
|
股本变动
|
529.70万
|
148.80万
|
420.30万
|
97.26万
|
|
发行/削减债务净额
|
71.90万
|
63.50万
|
246.30万
|
176.41万
|
|
其他融资基金
|
--
|
--
|
--
|
--
|
|
筹资现金流
|
601.60万
|
212.30万
|
666.60万
|
273.67万
|
|
汇率影响
|
149.70万
|
-8.10万
|
-17.40万
|
-4.67万
|
|
杂项基金
|
--
|
--
|
--
|
--
|
|
现金净流动
|
262.50万
|
-327.70万
|
285.40万
|
126.32万
|
|
自由现金流
|
-480.80万
|
-520.80万
|
-368.80万
|
-143.40万
|
公司高管
|
David Sidransky
|
Founder of Champions Oncology, Inc. and Israel Biotech Fund, David Sidransky currently is Chairman for Advaxis, Inc., Chairman of Tamir Biotechnology, Inc. and General partner at Israel Biotech Fund. Dr. Sidransky is also Professor at The Johns Hopkins University, Professor at The Johns Hopkins Hospital, Inc., Executive Officer of Biomerk, Inc., Director-Head & Neck Cancer Research Division at The Sidney Kimmel Comprehensive Cancer Center, Director-Head & Neck Cancer Research Division at The Johns Hopkins University School of Medicine and Professor at John Hopkins University and on the board of 6 other companies.
In the past Dr. Sidransky held the position of Senior Editor at Clinical Cancer Research.
David Sidransky received an undergraduate degree from Brandeis University and a doctorate from Baylor College of Medicine.
|
|
Vered Caplan
|
Vered Caplan is a businessperson who has been the head of 5 different companies and currently occupies the position of Chairman, President & Chief Executive Officer for Orgenesis, Inc. and Chairman at ATVIO Biotech Ltd. and President at MaSTherCell Global, Inc. (both are subsidiaries of Orgenesis, Inc.). Ms. Caplan is also on the board of 6 other companies.
In her past career Ms. Caplan was Chief Executive Officer at Kamedis and Chief Executive Officer at Gammacan International, Inc.
Vered Caplan received a graduate degree from Tel-Aviv University and an undergraduate degree from Technion-Israel Institute of Technology.
|
|
Neil Reithinger
|
Founder of Eventus Advisory Group LLC, Eventus Consulting PC and Sustinere Holdings, Inc., Neil Reithinger is an entrepreneur and businessperson who has been at the head of 10 different companies and presently is Director, Chief Executive & Financial Officer for Peak Pharmaceuticals, Inc., President, CEO, CFO, Treasurer & Director at Intellisense Solutions, Inc., President, Treasurer & Director at Sustinere Holdings, Inc., President for Eventus Consulting PC, President of Eventus Advisory Group LLC, President at Site 85 Productions, Inc., Chief Financial Officer, Secretary & Treasurer of Orgenesis, Inc. and Chief Financial Officer at ArtVentive Medical Group, Inc. Neil Reithinger is also Member of Arizona Society of Certified Public Accountants and Member of The American Institute of Certified Public Accountants.
In the past Mr. Reithinger was Chief Operations & Financial Officer at New Leaf Brands, Inc., President at Strategic Healthcare Systems, Inc., President at Carolco Pictures, Inc., Chief Financial Officer at NaturalShrimp, Inc. and Chief Executive Officer at Nutritional Specialties, Inc.
Neil Reithinger received an undergraduate degree from the University of Arizona.
|
|
Yaron Adler
|
Founder of Perion Network Ltd. and Mircod SiP, Yaron Adler is on the board of Inneractive Ltd. and 5 other companies. In the past Mr. Adler occupied the position of President for Perion Network Ltd. and Product Manager at Tecnomatix Technologies Ltd.
Mr. Adler received an undergraduate degree from Tel-Aviv University.
|
|
Guy Yachin
|
Guy Yachin is a businessperson who founded Chiasma, Inc. and who has been at the head of 5 different companies. Mr. Yachin is President & Chief Executive Officer at Serpin Pharma, LLC. He is also on the board of Orgenesis, Inc., Thera-P Ltd. and Exxel Pharma, Inc.
He previously occupied the position of Chief Executive Officer at Naiot Technological Center Ltd., Chief Executive Officer & General Manager of Therapix Biosciences Ltd., Chief Executive Officer at VESSL Therapeutics Ltd., Chief Executive Officer at Chiasma, Inc. and Senior Consultant at Ofer Technologies Ltd.
Mr. Yachin received an undergraduate degree and an MBA from Technion-Israel Institute of Technology.
|
|
David Sidransky
|
Founder of Champions Oncology, Inc. and Israel Biotech Fund, David Sidransky currently is Chairman for Advaxis, Inc., Chairman of Tamir Biotechnology, Inc. and General partner at Israel Biotech Fund. Dr. Sidransky is also Professor at The Johns Hopkins University, Professor at The Johns Hopkins Hospital, Inc., Executive Officer of Biomerk, Inc., Director-Head & Neck Cancer Research Division at The Sidney Kimmel Comprehensive Cancer Center, Director-Head & Neck Cancer Research Division at The Johns Hopkins University School of Medicine and Professor at John Hopkins University and on the board of 6 other companies.
In the past Dr. Sidransky held the position of Senior Editor at Clinical Cancer Research.
David Sidransky received an undergraduate degree from Brandeis University and a doctorate from Baylor College of Medicine.
|
|
Vered Caplan
|
Vered Caplan is a businessperson who has been the head of 5 different companies and currently occupies the position of Chairman, President & Chief Executive Officer for Orgenesis, Inc. and Chairman at ATVIO Biotech Ltd. and President at MaSTherCell Global, Inc. (both are subsidiaries of Orgenesis, Inc.). Ms. Caplan is also on the board of 6 other companies.
In her past career Ms. Caplan was Chief Executive Officer at Kamedis and Chief Executive Officer at Gammacan International, Inc.
Vered Caplan received a graduate degree from Tel-Aviv University and an undergraduate degree from Technion-Israel Institute of Technology.
|
|
Neil Reithinger
|
Founder of Eventus Advisory Group LLC, Eventus Consulting PC and Sustinere Holdings, Inc., Neil Reithinger is an entrepreneur and businessperson who has been at the head of 10 different companies and presently is Director, Chief Executive & Financial Officer for Peak Pharmaceuticals, Inc., President, CEO, CFO, Treasurer & Director at Intellisense Solutions, Inc., President, Treasurer & Director at Sustinere Holdings, Inc., President for Eventus Consulting PC, President of Eventus Advisory Group LLC, President at Site 85 Productions, Inc., Chief Financial Officer, Secretary & Treasurer of Orgenesis, Inc. and Chief Financial Officer at ArtVentive Medical Group, Inc. Neil Reithinger is also Member of Arizona Society of Certified Public Accountants and Member of The American Institute of Certified Public Accountants.
In the past Mr. Reithinger was Chief Operations & Financial Officer at New Leaf Brands, Inc., President at Strategic Healthcare Systems, Inc., President at Carolco Pictures, Inc., Chief Financial Officer at NaturalShrimp, Inc. and Chief Executive Officer at Nutritional Specialties, Inc.
Neil Reithinger received an undergraduate degree from the University of Arizona.
|
|
Yaron Adler
|
Founder of Perion Network Ltd. and Mircod SiP, Yaron Adler is on the board of Inneractive Ltd. and 5 other companies. In the past Mr. Adler occupied the position of President for Perion Network Ltd. and Product Manager at Tecnomatix Technologies Ltd.
Mr. Adler received an undergraduate degree from Tel-Aviv University.
|
|
Guy Yachin
|
Guy Yachin is a businessperson who founded Chiasma, Inc. and who has been at the head of 5 different companies. Mr. Yachin is President & Chief Executive Officer at Serpin Pharma, LLC. He is also on the board of Orgenesis, Inc., Thera-P Ltd. and Exxel Pharma, Inc.
He previously occupied the position of Chief Executive Officer at Naiot Technological Center Ltd., Chief Executive Officer & General Manager of Therapix Biosciences Ltd., Chief Executive Officer at VESSL Therapeutics Ltd., Chief Executive Officer at Chiasma, Inc. and Senior Consultant at Ofer Technologies Ltd.
Mr. Yachin received an undergraduate degree and an MBA from Technion-Israel Institute of Technology.
|
高管交易状态
持股状况
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
|---|---|---|---|---|---|
|
Merrill Lynch & Co Inc
|
200
|
--
|
-863
|
-81.19%
|
2018-06-30
|
|
SevenBridge Financial Group, LLC
|
250
|
--
|
250
|
--
|
2018-03-31
|
|
Ayalon Mutual Funds Ltd.
|
650
|
--
|
650
|
--
|
2018-06-30
|
|
Winslow Evans & Crocker Inc
|
1000
|
0.01%
|
1000
|
--
|
2018-03-31
|
|
Citigroup Inc
|
1303
|
0.01%
|
--
|
--
|
2018-06-30
|
|
Alumot Mutual Funds Management Ltd
|
3250
|
0.02%
|
--
|
--
|
2018-06-30
|
|
Panagora Asset Management Inc
|
4626
|
0.04%
|
4626
|
--
|
2018-03-31
|
|
Morgan Stanley Smith Barney LLC
|
10125
|
0.08%
|
--
|
--
|
2018-06-30
|
|
Universite Libre de Bruxelles
|
408792
|
0.34%
|
408792
|
--
|
2017-11-13
|
|
BlackRock Inc
|
19167
|
0.14%
|
19167
|
--
|
2018-06-30
|
|
Vanguard Group Inc
|
144817
|
1.09%
|
144817
|
--
|
2018-06-30
|
|
UBS Securities LLC
|
56
|
--
|
56
|
--
|
2018-06-30
|
|
Royal Bank Of Canada
|
500
|
--
|
500
|
--
|
2018-03-31
|
|
FMG LLC
|
1291
|
0.01%
|
1291
|
--
|
2018-06-30
|
|
BlackRock Fund Advisors
|
18686
|
0.13%
|
--
|
--
|
2018-08-30
|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
|---|---|---|---|---|---|
|
Vanguard Extended Market Idx Inv
|
143392
|
0.98%
|
--
|
--
|
2018-07-31
|
|
iShares Micro-Cap
|
18686
|
0.11%
|
--
|
--
|
2018-09-12
|
|
The Vanguard Total Stock Market Index
|
1425
|
0.01%
|
--
|
--
|
2018-07-31
|
|
AXA/Lord Abbett Micro Cap K
|
1291
|
0.01%
|
--
|
--
|
2018-07-31
|
